Skip to main content
. Author manuscript; available in PMC: 2021 Jul 8.
Published in final edited form as: Nano Lett. 2020 Jun 8;20(7):4857–4863. doi: 10.1021/acs.nanolett.0c00757

Figure 4.

Figure 4.

In vivo antitumor efficacy and gene silencing of HRNP/siCDC20 on MCF-7 tumor-bearing BALB/c nude mice. (A) Timetable of construction of MCF-7 tumor-bearing BALB/c nude mice model and treatment strategy. (B) Individual and (C) average tumor growth curves in each treatment group. (D) Tumor inhibition rate and tumor weight toward MCF-7 tumor-bearing mice after treatment with Ctrl, siCDC20, HRNP/siCtrl, or HRNP/siCDC20. (F) Western blot and quantitative analyses of CDC20 expression in the Ctrl and HRNP/siCDC20 group. Immunofluorescence staining of (G) CDC20, (H) cyclin B (H), and (I) Mcl-1 expression in MCF-7 tumor tissues of xenograft mice after treatment with Ctrl, siCDC20, HRNP/siCtrl, or HRNP/siCDC20. Scale bar is 50 μm. (J) TUNEL of tumor tissue sections to detect tumor apoptosis in each treatment group. Scale bar is 50 μm. The nuclei and apoptotic cells are stained blue and green, respectively. The statistical data are presented as mean ± SD (n = 5 for in vivo study, n = 3 for ex vivo study; ***P < 0.001).